Replies to post #273091 on Avid Bioservices Inc (CDMO)

[entdoc]

wildhorses, nice post. Mostly in agreement. Management has said, "we have it". They have not stepped a foot wrong in that regard. If this subset can be identified early on in the treatment cycle, long before end-stage disease, we have a winner, depending on what percentage of responders we are talking about. If we have a biomarker for 1% of the population of diseased subjects vs., say, 30%, then we are in business. Lung cancer involves an enormous demographic worldwide. You think it's bad here. Think China. makes me wonder about 2C3 in Russia.

[Protector]

Wildhorse, excellent post. You will not be disappoints by the PPHM or 3rd party PPHM related presentations in the coming months. Believe me, NOBODY, IMO, will be disappointed...unless they are PPHM unfriendly of course :)

[TekNuLoof]

WH, excellent point of view!
I'm in the same room as you, although I am consuming vast quantities of pure kentucky Korn Licker, reassembling a space-like vehicle and rebuilding my shack all while listening intently to the choice words being whispered by the fine folks here on this board and at Peregrine.

Jmo
Loofman